FibroGen (NASDAQ:FGEN – Get Rating) and Ovid Therapeutics (NASDAQ:OVID – Get Rating) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, analyst recommendations, profitability, dividends and earnings.
Profitability
This table compares FibroGen and Ovid Therapeutics' net margins, return on equity and return on assets.
Get
FibroGen alerts:
| Net Margins | Return on Equity | Return on Assets |
| FibroGen | -109.22% | -109.09% | -35.42% |
| Ovid Therapeutics | N/A | -37.03% | -34.18% |
Analyst Ratings
This is a summary of current recommendations and price targets for FibroGen and Ovid Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
| FibroGen | 1 | 1 | 1 | 0 | 2.00 |
| Ovid Therapeutics | 0 | 2 | 0 | 0 | 2.00 |
FibroGen currently has a consensus target price of $19.00, suggesting a potential upside of 30.14%. Ovid Therapeutics has a consensus target price of $2.40, suggesting a potential upside of 9.09%. Given FibroGen's higher possible upside, research analysts plainly believe FibroGen is more favorable than Ovid Therapeutics.
Valuation & Earnings
This table compares FibroGen and Ovid Therapeutics' top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
| FibroGen | $235.31 million | 5.79 | -$290.02 million | ($3.04) | -4.80 |
| Ovid Therapeutics | $208.38 million | 0.74 | $122.83 million | ($1.01) | -2.18 |
Ovid Therapeutics has lower revenue, but higher earnings than FibroGen. FibroGen is trading at a lower price-to-earnings ratio than Ovid Therapeutics, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
FibroGen has a beta of 0.87, suggesting that its share price is 13% less volatile than the S&P 500. Comparatively, Ovid Therapeutics has a beta of 1.24, suggesting that its share price is 24% more volatile than the S&P 500.
Insider and Institutional Ownership
77.4% of FibroGen shares are held by institutional investors. Comparatively, 48.3% of Ovid Therapeutics shares are held by institutional investors. 2.8% of FibroGen shares are held by company insiders. Comparatively, 10.7% of Ovid Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Summary
Ovid Therapeutics beats FibroGen on 8 of the 13 factors compared between the two stocks.
About FibroGen
(Get Rating)
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
About Ovid Therapeutics
(Get Rating)
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies. It also develops OV882, a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815 for the treatment of kinesin-family of proteins associated neurological disorder. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.
